Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Binding together for biomarkers
September 2018
SHARING OPTIONS:

TUCSON, Ariz.—August saw the completion of a master agreement between HTG Molecular Diagnostics Inc. and Oncologie Inc. under which the companies will partner to develop biomarkers associated with Oncologie's immuno-oncology pipeline. No specific details were disclosed, but Oncologie's website lists two pipeline compounds at present: bavituximab, a TIM/TAM ligand antibody in Phase 2 development with opened or anticipated trials in hepatocellular carcinoma, glioblastoma multiforme and head and neck cancer, with additional trials intended in Asian-prevalent solid tumors; and lefitolimod, a TLR9 agonist in Phase 3 development with opened or anticipated trials in colorectal cancers and in solid tumors with checkpoint inhibitors.
 
Dr. Laura Benjamin, CEO and founder of Oncologie, said in a press release that, “We believe HTG’s technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.